

# Journal of Visualized Experiments

## Characterizing the Relationship between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking --Manuscript Draft--

|  |  |
|--|--|
| Article Type:  | Invited Methods Article - JoVE Produced Video  |
| Manuscript Number:   | JoVE60052R2  |
| Full Title:  | Characterizing the Relationship between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking |
| Keywords:  | Parkinson's disease; Cognition; Cognitive impairment; Eye tracking; Eye movement; Saccade; Visual fixation   |
| Corresponding Author:  | Oscar Wong, M.B., Ch.B., FHKCPsych<br>Tai Po Hospital<br>Hong Kong, nil HONG KONG  |
| Corresponding Author's Institution:  | Tai Po Hospital  |
| Corresponding Author E-Mail:   | oscarwongwh@gmail.com;oscarwhwong@cuhk.edu.hk  |
| Order of Authors:  | Oscar WH Wong, M.B., Ch.B., FHKCPsych<br>Gabriel PC Fung<br>Sandra Chan  |
| Additional Information:  |  |
| Question   | Response   |
| Please indicate whether this article will be Standard Access or Open Access.   | Standard Access (US\$2,400)  |
| Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations. | Hong Kong  |

Dr. Ronald Myers  
Senior Science Editor, Journal of Visualized Experiments  
1 Alewife Center Suite 200 Cambridge MA 02140

28<sup>th</sup> March 2019

Dear Dr. Myers,

We are a group of researchers in neuropsychiatry based in Hong Kong, China. We would appreciate your consideration of an article, “Characterizing the Relationship between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson’s Disease Patients with Eye Tracking” for publication in the Journal of Visualized Experiments.

Parkinson’s disease is a chronic debilitating neurodegenerative disease that patients suffer from a variety of cognitive deficits on top of the motor symptoms. Our current study explored the clinical utility of eye tracking technology as an adjunctive biomarker of cognitive functions in Parkinson’s disease. In the experiment, we used a visual search task coupled with an eye tracker to capture metrics of saccade and fixation to establish correlations with individual cognitive functions in a case-control study of non-demented Parkinson’s disease patients.

The experimental design allowed us to study in-depth on the relationship between eye-movement metrics and cognitive functions on a phenomenological level. With our existing knowledge of cognitive neuroscience and physiology of eye movement control, we are able to infer postulations to the observed results. For example, we found that visual fixation duration correlates negatively with performances in visual memory, verbal recognition memory, and semantic verbal fluency. We postulate a possible common confluence at the temporal and parietal region of the brain with a cholinergic type of deficit that accounted for the observed correlations. The findings encourage us to further explore the longitudinal relationship between the two functions. The paradigm was highly tolerable to our subjects and it has the potential to be applied transdiagnostically in other neurocognitive disorders to explore similar research question. Therefore, we would like to share our experimental design and set-up with researchers working in a similar field.

This paper is not under consideration for publication elsewhere. All co-authors have read the manuscript. Thank you very much for your time in considering our paper.

Yours sincerely,

Dr. Oscar Wong  
M.B., Ch.B. (CUHK), FHKCPsych, FHKAM (Psychiatry)  
Resident Specialist,  
Department of Psychiatry,  
Tai Po Hospital, Hong Kong SAR

**TITLE:**

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-Demented Parkinson's Disease Patients with Eye Tracking

**AUTHORS & AFFILIATIONS:**

Oscar WH Wong<sup>1</sup>, Gabriel PC Fung<sup>2</sup>, Sandra Chan<sup>1</sup>

<sup>1</sup>Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong SAR

<sup>2</sup>Lab Viso Limited, Kowloon, Hongkong

Corresponding Author:

Oscar WH Wong (oscarwhwong@cuhk.edu.hk)

Email Address of Co-Author:

Gabriel PC Fung (gabriel@labviso.com)

Sandra Chan (schan@cuhk.edu.hk)

**KEYWORDS:**

Parkinson's disease, cognition, cognitive impairment, eye tracking, eye movement, saccade, visual fixation

**SUMMARY:**

Here, we present a protocol to study the relationship between the eye movement parameters and cognitive functions in non-demented Parkinson's disease patients. The experiment used an eye tracker to measure the saccadic amplitude and fixation duration in a visual search task. The correlation with performance in multi-domain cognitive tasks was subsequently measured.

**ABSTRACT:**

Cognitive impairment is a common phenomenon in Parkinson's disease that has implications on the prognosis. A simple, noninvasive and objective proxy measurement of cognitive function in Parkinson's disease will be helpful in detecting early cognitive decline. As a physiological metric, eye movement parameter is not confounded by the subject's attributes and intelligence and can function as a proxy marker if it correlates with cognitive functions. To this end, this study explored the relationship between the eye movement parameters and performance in cognitive tests in multiple domains. In the experiment, a visual search task with eye tracking was set up, where subjects were asked to look for a number embedded in an array of alphabets scattered randomly on a computer screen. The differentiation between the number and the alphabet is an overlearned task such that the confounding effect of cognitive ability on the eye movement parameters is minimized. The average saccadic amplitude and fixation duration were captured and calculated during the visual search task. The cognitive assessment battery covered domains of frontal-executive functions, attention, verbal and visual memory. It was found that prolonged fixation duration was associated with poorer performance in verbal fluency, visual and verbal memory, allowing further exploration on the use of eye movement parameters as proxy markers for cognitive function in Parkinson's disease patients. The experimental paradigm has been found

to be highly tolerable in our group of Parkinson's disease patients and could be applied transdiagnostically to other disease entities for similar research questions.

## **INTRODUCTION:**

Parkinson's disease is classically a motor disorder; yet, the disease is also associated with cognitive deficits, and progression into dementia is common<sup>1</sup>. The pathophysiology of cognitive impairment in Parkinson's disease is not well understood. It is thought to be related to alpha-synuclein deposition in the cortical area based on Braak's staging<sup>2</sup>. It was also proposed that a dual syndrome of degeneration of the dopaminergic and the cholinergic system leads to different cognitive deficits with prognostic implication<sup>3</sup>. More research is needed to further elucidate the exact mechanisms involved in cognitive impairment in Parkinson's disease. On the clinical aspect, the presence of cognitive impairment has a significant impact on prognosis<sup>4,5</sup>. Assessment of cognitive function in clinical practice is, therefore, essential. However, a lengthy cognitive assessment is limited by patients' mental and motor conditions. Therefore, a noninvasive and simple measurement that can reflect the disease's burden on cognitive function is needed.

The eye movement abnormalities are widely described detectable signs of Parkinson's disease from its early stages<sup>6</sup>, yet the pathophysiology is even less well-characterized than that of cognitive impairment. The generation of eye movement is through a transformation of the visual sensory input, subserved by an intertwined cortical and subcortical network, into signals to the oculomotor nuclei in the brainstem for effect<sup>7</sup>. Involvement of Parkinson's disease pathologies in these networks may lead to observable eye movement abnormalities. There is, perhaps overlapping of neuroanatomical structures that govern the control of eye movement and cognitive function. Furthermore, there have been studies examining the relationship between saccadic eye movement and cognitive function in other neurodegenerative disorders<sup>8</sup>. On such grounds, it is worthwhile to explore the use of eye movement parameters as a proxy marker of cognitive functions in Parkinson's disease. One cross-sectional study<sup>9</sup> showed that reduced saccadic amplitude and longer fixation duration was associated with the severity of global cognitive impairment in Parkinson's disease. However, there is a lack of data on the correlation between eye movement parameters and specific cognitive domains. The significance and need of measurement of specific cognitive domains, rather than a general cognitive state, is that individual cognitive domain informs differential prognostic information in Parkinson's disease<sup>3</sup> and they are subserved by different neural networks. The aim of this study is to explore the specific relationship between eye movement metrics and different cognitive functions. This is the first step to establish a foundation on which the development of biomarkers of cognitive decline in Parkinson's disease using eye tracking technology could be built.

The experimental paradigm presented is composed of 2 major parts: the cognitive assessment and the eye tracking task. The cognitive assessment battery encompassed a range of cognitive functions, including attention and working memory, executive function, language, verbal memory and visuospatial function. The choice of these 5 cognitive domains is based on the Movement Disorder Society Task Force Guidelines for the mild cognitive impairment in Parkinson's disease<sup>10</sup>, and a set of locally available cognitive tests were selected to build the assessment battery. In a previous similar eye tracking study on Parkinson's disease cognition

mentioned<sup>9</sup>, the author extracted the eye movement parameters while the subjects were engaged in visual cognitive tasks, where the parameters may potentially be influenced by the subject's cognitive ability. As this study aimed to assess the correlation between the eye movement parameters and different cognitive domains, the potential confounding effect of cognitive abilities on the eye parameters must be addressed. In this regards, a visual search task, adapted from another eye tracking study on Alzheimer's disease<sup>11</sup>, was employed to capture the eye movement parameters of the subjects. During the task, subjects had to search for a single number on a computer screen among multiple alphabet distracters. This task would elicit the alternate use of saccadic eye movement and visual fixation, the abnormalities of which are described widely in Parkinson's disease. The identification and differentiation of number and alphabet is an overlearned task where the demand for cognitive functions is only minimal and would, therefore, be suitable to answer the research question of this study. A computer program was developed based on the specifications and design as stated by Rösler et al<sup>11</sup>. in their original study to be run within the in-built software of our eye tracker. An in-house algorithm for classification and analysis of the eye tracking data was also developed for this study.

## **PROTOCOL:**

This research project was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (CREC Ref. No.: 2015.263).

### **1. Participants recruitment and baseline assessment**

1.1. Recruit Parkinson's disease patients aged less than or equal to 70 from a neurology specialist clinic with the diagnosis made based on the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Diagnostic Criteria<sup>12</sup>.

1.1.1. Exclude subjects with psychiatric illnesses, ophthalmological diseases that would impair eye movement, or other neurological disorders. Also, exclude cases using anticholinergics as they are known to affect cognitive performance and eye movement.

1.2. Recruit healthy controls on a 1:1 basis matched by sex, age, and education.

1.3. Obtain informed consent from the subject.

1.4. Conduct a clinical diagnostic interview with the subject and, if available, their relatives, to exclude dementia and screen for cognitive impairment with Mental State Examination (MMSE)<sup>13</sup> and Montreal Cognitive Assessment (MoCA)<sup>14</sup>. Exclude dementia cases from the study or if the subject's scores of either MMSE or MoCA is <22/30.

1.5. Assess the visual acuity with a Snellen chart. Exclude the subject if the visual acuity is less than 20/40.

1.6. Assess motor severity and staging of Parkinson's disease using the Unified Parkinson's

Disease Rating Scale (UPDRS) Part II & III<sup>15</sup> and Modified Hoehn and Yahr (H&Y) Staging<sup>16</sup>, respectively. Also, obtain information about the current medications taken by the subject.

1.7. Assess the depressive mood state by the Beck Depression Inventory-II (BDI-II)<sup>17</sup>.

## **2. Experimental setup**

2.1. Conduct the experiment in a quiet room with an adequate light source.

2.2. Conduct the experiment for Parkinson's disease subjects when they are on medication with optimal motor function.

2.3. Prepare the setup that consists of a screen-based eye tracker, a computer, a mouse, a standard keyboard, a chin rest, and cognitive assessment tools (**Table of Materials**).

2.4. Use an eye tracker with a sampling rate of at least 300 Hz.

2.5. Place the chin rest 60 cm in front of the eye tracker screen.

## **3. The flow of the cognitive assessment and the visual search task**

3.1. Carry out the Chinese Categorical Verbal Fluency Test<sup>18</sup>. Instruct the subject to name as many animals as possible in a minute. Record the number of answers and perseverative error. Then repeat the same in the category of fruits and vegetables.

3.2. Conduct the registration part (Trial 1, 2 and 3) of the Hong Kong List Learning Test (HKLLT)<sup>19</sup> by reading out a pre-defined 16-vocabulary word list and instruct the subject to remember them. Afterwards ask the subject to do free recall of the word list and record the answer (Trial 1).

3.2.1. Repeat step 3.2 twice for Trial 2 and Trial 3.

3.3. Wait 10 min and 30 min after the registration part of the HKLLT for the 10- and 30-min delay recall.

3.4. Before the 10 min delayed recall of the HKLLT, perform the Pattern Recognition Memory (PRM) from Cambridge Neuropsychological Test Automated Battery (CANTAB)<sup>20</sup> (**Table of Material**).

3.4.1. Using the tablet computer, present 24 visual patterns, one at a time, at the center of the screen. Instruct the subject to remember the pattern.

3.4.2. After the presentation, in a 2-choice force discrimination paradigm, instruct the subject to choose the pattern that he/she can recognize.

- 177
- 178 3.5. Perform the 10 min delay recall of HKLLT by asking the subject to do free recall of the 16-
- 179 vocabulary word list.
- 180
- 181 3.6. Before the 30 min delayed recall of the HKLLT, perform Spatial Span (SSP) from CANTAB<sup>20</sup>.
- 182
- 183 3.6.1. Use the tablet computer to show a pattern of white boxes which change in color, one by
- 184 one, in variable sequences.
- 185
- 186 3.6.2. Afterwards instruct the subject to touch the boxes in the same sequence they were
- 187 presented and record the spatial span length that the subject could attain as the difficulty
- 188 (number of boxes change in color) of the task increases.
- 189
- 190 3.7. Carry out the 30 min delay recall by asking the subject to do free recall of the 16-
- 191 vocabulary word list.
- 192
- 193 3.7.1. Conduct the recognition and discrimination part of the HKLLT by reading out another pre-
- 194 defined 32-vocabulary word list, of which half of the vocabularies are from the original word list
- 195 in 3.2. Instruct the subject to determine whether each vocabulary read out is from the original
- 196 word list or not.
- 197
- 198 3.8. Allow the subject to rest quietly if they finish the tasks in 3.4 and 3.6 before the 10- and
- 199 30-min delay recall, respectively.
- 200
- 201 3.9. Perform the Stocking of Cambridge (SOC) from CANTAB<sup>20</sup>.
- 202
- 203 3.9.1. Using the tablet computer, present 20 scenarios of two parallel displays of 3 balls held in
- 204 3 vertical stockings, of which the arrangement of the balls in the displays varies in each scenario.
- 205
- 206 3.9.2. Instruct the subject to determine, in each scenario, the least number of moves required
- 207 to rearrange the balls in the lower display in order to copy the pattern shown in the upper display.
- 208 Record the mean number of choices to correct answer.
- 209
- 210 3.10. Perform the Stroop Test<sup>21</sup>.
- 211
- 212 3.10.1. Give the subject 3 cards consecutively; the first card contains dots printed in different
- 213 colors, the second card contains Chinese characters printed in different colors while the last card
- 214 has Chinese characters denoting different colors (e.g., Chinese words of "blue", "yellow",
- 215 "green", or "red") but printed in a color not denoted by the name (e.g., the word "red" printed
- 216 in blue ink).
- 217
- 218 3.10.2. Ask the subject to read out the printed color of the dots/Chinese characters as quickly as
- 219 possible and record the time required for each card (T1, T2, and T3).
- 220

3.10.3. Calculate the interference index with the formula  $(T3-T1)/T1$ .

3.11. Proceed to the visual search task after completing the cognitive tests.

NOTE: Do not carry out any verbal cognitive task after the registration part of HKLLT until the end of the whole HKLLT (3.7) to prevent interference effect on verbal memory performance.

#### 4. Visual search task

4.1. Position the subject on a chair and place their chin on the chin rest with their forehead against a bar to minimize head movement. Align the subject's eyes to approximately the center of the computer screen. Begin by clicking the **Start Recording** button in the computer program.

#### 4.2. Calibration

4.2.1. Calibrate the eye tracker with the in-built calibration program by clicking the **Start** button in the calibration interface.

4.2.2. Ask the subject to gaze at a red dot moving across the screen with 9 fixation points, while keeping the head still.

4.2.3. Check for the quality of the calibration by viewing the calibration plot (**Figure 1**). Make sure that the length of the green lines, which represent the error vectors, fall within the grey circles for an acceptable quality of the calibration. Redo the calibration if there is any missing point or the green lines fall outside the grey circles. Click **Accept** to proceed to the visual search task.

#### 4.3. Instruction

4.3.1. Provide verbal instruction to the subject and start with 5 practice runs to familiarize the subject with the task.

4.3.2. Instruct the subject to fixate their gaze on the central fixation cross at the beginning of each trial. Then, press **Enter** on the keyboard to begin a trial, at which the computer screen will display a single number and 79 distracter alphabets scattered randomly (**Figure 2**).

4.3.3. Instruct the subject to look as quickly as possible for the number and then simultaneously click on the mouse and state the number aloud as soon as the number is located.

4.3.4. Cross check if the number stated is correct or not.

4.3.5. Administer a total of 40 trials after the 5 practice runs.

#### 4.4. Design of the trial images in the visual search task



NOTE: The program code, written in PHP, for this section can be found in **Supplement File 1**.

4.4.1. Use the numbers 4, 6, 7 and 9 exclusively (**Supplementary File 1** - Line 5).

NOTE: The pilot study<sup>11</sup> showed that these numbers are most easily discriminated from the alphabets.

4.4.2. Ensure that the location of the target number is randomized from trial to trial with the rule that it could not be in the same visual quadrant for more than three successive trials (**Supplementary File 1** - Line 48-52).

4.4.3. Do not use ambiguous alphabets such as “I” and “O” (**Supplementary File 1** - Line 76-78).

4.4.4. Set the size of the fixation cross, alphabets, and numbers at 0.85° visual angle (equivalent to around 0.9 cm on a 23 inches computer screen).

NOTE: Numbers and alphabets are used because these are easily recognizable visual stimuli yet require foveation for identification.

4.4.5. Allow a time lapse of 1.5 s after the investigator has pressed **Enter** in 4.3.2 and before the display of the central fixation cross is switched to a trial image to begin a trial (**Supplementary File 2** - Line 71; 156-158).

4.4.6. Ensure that the screen will go blank with the fixation cross reappearing as the mouse is clicked or after 10 s have elapsed since the beginning of a trial, whichever that is earlier (**Supplementary File 2** - Line 72; 162-180).

4.4.7. As the task is finished, generate a .csv file that contains the timestamps of the beginning and the end of each trial (**Supplementary File 2** – line 48-59; 199-208). Use this file in the data analysis in section 5.

## **5. Eye tracking data processing and analysis**

5.1. In the **Replay** section of the computer program, check the Samples Percentage of the eyes during the visual search task (**Figure 3**). Discard the subject’s data if more than 20% missing data are observed.

NOTE: Samples Percentage denotes the percentage of time the eyes are successfully located by the eye tracker during the visual search task.

5.2. Click on the **Play** button for the recording to check the quality of the data by eyeballing the visualized scan path video generated (**Figure 4**). Discard the whole subject’s data if it is grossly erroneous (**Figure 5**).

5.3. Discard any trial(s) in which the subject pressed the mouse accidentally and prematurely.

5.4. In the **Data Export** section of the program, select **GazePointX (ADCSpX)** and **GazePointY (ADCSpY)** and the subject of interest (**Figure 6**). Click **Export Data** to export each subject's data and save as a .csv file. The file contains the x and y coordinates of the subject's eyes position on the computer screen, in pixels, at every time point.

5.5. Use the Visual Search Analyzer and in the interface (**Figure 7**), select the data exported in 5.4 as the input of **Eye Data** and the .csv file generated in 4.4.7 as the input of **Action data**. Select **ST DBScan** as the classification algorithm and click on **Run**. Then, click on **Summary** to generate a spreadsheet file containing the mean saccade amplitude and the mean fixation duration of the subject.

5.6. Design of the visual search analyzer

NOTE: The coding for the design of the analyzer could be found at <https://github.com/lab-viso-limited/visual-search-analyzer>. Its program code can be found in **Supplementary File 3**.

5.6.1. Program the analyzer such that it extracts and analyzes only the data from the beginning to the end of the trial (i.e., from the display of the number and alphabets until the mouse is clicked or 10 s have elapsed), using the .csv file generated in 4.4.7 (**Supplementary File 3** - Line 6-173).

5.6.2. Program the analyzer such that it fills in the data loss due to eye-blinking by averaging the x and y coordinates of the gaze point immediately before and after the blinking (**Supplementary File 3** - Line 176-260).

5.6.3. Program the analyzer such that it classifies the raw data into either saccade or fixation by using the algorithm developed based on ST-DBSCAN<sup>22</sup> (Program code in **Supplementary File 4**).

## REPRESENTATIVE RESULTS:

The full result of this study is available in the original paper published<sup>23</sup>. Parkinson's disease subjects (n = 67) were recruited and completed the assessment. However, 5 cases failed to complete the visual search task as they wore progressive lens incompatible with the eye tracker and their data was discarded. The mean age of the subjects was 58.9 years (SD = 7.5 years) with a male to female ratio of 1.7:1. 62 healthy age-, sex-, and education-matched controls were recruited for comparison.

### Cognitive and eye movement parameters

Consistent with other previous studies<sup>24</sup>, the Parkinson's disease group showed poorer performance in multiple cognitive tasks as compared to the control group (**Table 1**). Using the in-house algorithm for classification of the visual search task data, fixations and saccades are identified and extracted for calculation and analysis. It was found that the disease group had a

smaller mean saccadic amplitude ( $16.36^{\circ} \pm 2.36$ ) as compared to controls ( $17.27^{\circ} \pm 2.49$ ;  $p = 0.037$ ). The mean fixation duration was not significantly different between the groups ( $216.58 \text{ ms} \pm 31.64$  vs,  $211.59 \text{ ms} \pm 24.90$ ;  $p = 0.331$ ) (**Table 2**).

### **Correlation between eye movement parameters and cognitive function**

After adjusting for covariates, there were negative correlations found between the mean fixation duration and the performance in verbal recognition memory score (Recognition and Discrimination scores;  $F = 5.843$ ,  $t = -2.417$ ,  $p = 0.017$  and  $F = 12.771$ ,  $t = -3.574$ ,  $p = 0.001$ , respectively), pattern recognition memory ( $F = 5.505$ ,  $t = -2.346$ ,  $p = 0.021$ ) and categorical verbal fluency test in the categories of fruit ( $F = 5.647$ ,  $t = -2.376$ ,  $p = 0.009$ ) and vegetable ( $F = 9.744$ ,  $t = -3.122$ ,  $p = 0.002$ ). (**Table 3**). However, there was no significant interaction found in these correlations between the disease and control group, suggesting that the correlations are not specific to the disease group. It is speculated that as the control of visual fixation and the correlated cognitive functions commonly involve temporal and parietal regions of the brain with a predominantly cholinergic basis, pathological changes to these neuroanatomical and biochemical mechanisms may explain the findings.

### **FIGURE AND TABLE LEGENDS:**

**Figure 1: A calibration plot of the eye tracker.** The plot shows the result of the calibration. The length of each green line indicates the difference between the gaze point calculated by the eye tracker and the actual dot position. As all the green lines fall within the grey circles and there is no missing point, the quality of this calibration is acceptable.

**Figure 2: An example of a trial of the visual search task.** Display of a non-linear array of 80 stimulus items, of which there is 1 number among 79 distracter alphabets.

**Figure 3: The interface to check the overall sampling percentage.** In the Replay section of the computer program, the Samples Percentage, which denotes the percentage of time that the eyes are successfully located by the eye tracker during the visual search task, could be checked for each subject.

**Figure 4: An example of a visualized scan path from the visual search task.** The scan path during this trial was visualized, with the red straight lines representing the saccadic eye movement and the red dots for visual fixations. Note that the end of each visual fixation is followed by a saccade and vice versa in a normal scan path.

**Figure 5: An example of a grossly erroneous visualized scan path.** This example of a grossly erroneous scan path is taken from a subject wearing a pair of incompatible progressive lens. In contrast to the normal scan path in **Figure 4**, the red lines (saccade) run in zigzag and fall out of the computer screen. The fixation points are not on either the alphabets or the number.

**Figure 6: The data export interface in the computer program.** This shows the interface where the subject and the kind of the eye tracking data captured can be selected for data export. In our experimental paradigm, the x and y coordinate, in pixels, of the eyes position on the screen at

every time point will be used for data analysis.

**Figure 7: The interface of the Visual Search Analyzer.** This shows the interface of the in-house analysis program for eye tracking data.

**Table 1: Comparison of cognitive scores between two groups using independent sample t-test.** MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; \* –  $p < 0.05$  <sup>a</sup> – mean choices to correct; <sup>b</sup> – scores transformed into z-score; <sup>c</sup> – percentage correct; <sup>d</sup> – span length. This table has been reproduced from<sup>23</sup>.

**Table 2: Comparison of eye tracking parameters between two groups using independent sample t-test.** \* -  $p < 0.05$ . This table has been modified from<sup>23</sup>.

**Table 3: Correlations between cognitive scores and eye-tracking parameters using General Linear Model: Significant findings only.** \* -  $p < 0.05$ . This table has been reproduced from<sup>23</sup>.

**Supplemental File 1:** Codes related to the trial image design.

**Supplemental File 2:** Codes related to the actual run of the visual search task.

**Supplemental File 3:** Codes related to the software (e.g., analyzer program).

**Supplemental File 4:** Codes related to the ST-DBSCAN algorithm used for classifying eye movement metrics.

## DISCUSSION:

The protocol presented above was designed as the first part of a longitudinal study in exploring the potential clinical utility of eye movement parameters as surrogate markers for cognitive functions in Parkinson's disease. While there are studies that examine more classical eye tracking paradigms such as self-paced saccade, reflexive saccade, and anti-saccade<sup>25,26,27</sup>, a visual search task was used in this study to measure eye movement parameters. As discussed, the design of this visual search task is of paramount importance as it must minimize the known confounding effect of a cognitive ability on the performance of the eye tracking task, as it may affect the eye movement parameters recorded. An example of which would be the effect of frontal executive functions on the saccadic latency<sup>28</sup>. The critical issue in the design would be the random scattering of the number and alphabets and varying quadrants of the number's location, making it more difficult to use cognitive strategies to enhance the performance of the task. Together with an average of roughly 650 saccades measured in 40 trials per subject, the average saccade amplitude calculated represents more of a physiological ability of the eye to generate saccade. In accordance with previous literature, it was found that the saccade amplitude is smaller in Parkinson's disease patients<sup>29,30</sup>. The choice of parameters extracted from the eye tracking task also needs to be taken care of with respect to the issue of the potential confounding effect by cognition. For example, parameters such as the speed of finding the number, error rate, and accuracy, which are a direct measurement of attention and processing speed, were not used.

Another critical step for this study is to ascertain the validity of the algorithm that was used in the classification of eye movement parameter. There exist numerous ways of classifying eye tracking data into saccade and fixation: velocity-based, dispersion-based algorithm and so on<sup>31</sup>. Each of these algorithms has its own pros and cons and there is no gold standard for doing so such that one has to also take into consideration the specifications of the eye tracker used and the design of eye tracking task to determine the best way of classifying the data. For this study, an in-house, density-based clustering algorithm, developed based on ST-DBSCAN<sup>22</sup>, was used. The research team has cross-validated the validity of this classification algorithm against manual classification in a pilot study before applying the algorithm to the data of this study. The computer program incorporating the algorithm would automatically splice out and classify the data within the trials, from the moment the trial starts (with the alphabets and number appearing on the screen) to the end (that the subject clicks on the mouse or 10 s has lapsed) so that no non-trial data recorded (e.g., during the display of the fixation cross) will be analyzed to contaminate the results.

The use of domain-specific cognitive tests in this study allow correlations of the eye movement parameters with individual cognitive function performance. As discussed, this has significance over using general overall cognitive measures as the neural circuitry and biochemical basis for each cognitive function are different. The contemporary knowledge on the neural mechanisms of eye movement control and individual cognitive functions allow us to make inference and interpretation of the results found. For example, the significant negative correlations of fixation duration with temporal-, parietal-, and cholinergic-based cognitive functions are of particular interest as impairment of these functions may predict the development of dementia<sup>3</sup>. Detailed discussions of the scientific basis that explain the correlations can be found in the original paper published<sup>23</sup>.

The battery of cognitive examination and the visual search task were highly tolerable to the subjects of this study. Requiring roughly 1.5 h to complete the entire battery, none of the subjects were unable to finish because of fatigue or physical discomfort. The visual search task consisted of 40 trials and took only around 5-10 min to complete. The noninvasive, simple and quick nature of the task makes it suitable as a screening tool if supported by more robust data. This paradigm could also be applied transdiagnostically in other neurocognitive disorders to answer similar research questions. One major practical limitation encountered in this protocol is the incompatibility of the eye tracker in subjects wearing certain progressive lens, as presbyopia is not an uncommon condition in the elderly. Eyelid apraxia and blepharospasm are also seen in Parkinson's disease<sup>32</sup> and sufferers of these conditions may not be able to complete the task.

As an explorative and cross-sectional study, the design of the study does not allow us to infer any definite neuroanatomical and biochemical basis that explains the results found. The interpretations of the results were mostly based on independent knowledge on the physiologies of cognitive functions and eye movement control and, therefore, remained as postulations. The longitudinal data on how these parameters may change over time during the neurodegenerative process is unknown. Yet, it is worthwhile to have a follow-up study to investigate the predictive

values of the baseline eye movement parameters on cognitive impairment development. Future studies should incorporate neuroimaging to address the neurostructural underpinnings for more solid support of any postulation, without which further development of eye tracking as a proxy marker of cognitive function will not be possible.

#### ACKNOWLEDGMENTS:

The authors would like to thank Dr. Harvey Hung for his advises on the manuscript.

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES:

1. Hely, M.A., Reid, W.G.J., Adena, M.A., Halliday, G.M., Morris, J.G.L. The Sydney Multicenter Study of Parkinson's disease: The inevitability of dementia at 20 years. *Movement Disorders*. **23** (6), 837-844 (2008).
2. Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., Rüb, U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). *Journal of Neurology*. **249** (0), iii1-iii5. (2002).
3. Williams-Gray, C.H. et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. *Brain*. **132** (11), 2958-2969, (2009).
4. Buter, T.C., van den Hout, A., Matthews, F.E., Larsen, J.P., Brayne, C., Aarsland, D. Dementia and survival in parkinson disease: A 12-year population study. *Neurology*. **70** (13), 1017-1022 (2008).
5. Aarsland, D., Larsen, J.P., Tandberg, E., Laake, K. Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. *Journal of the American Geriatrics Society*. **48** (8), 938-942 (2000).
6. Rascol, O. et al. Abnormal ocular movements in parkinson's disease: Evidence for involvement of dopaminergic systems. *Brain*. **112** (5), 1193-1214 (1989).
7. Orban De Xivry, J.J., Lefèvre, P. Saccades and pursuit: Two outcomes of a single sensorimotor process. *Journal of Physiology*. **584** (1), 11-23 (2007).
8. Crawford, T.J. et al. Inhibitory control of saccadic eye movements and cognitive impairment in Alzheimer's disease. *Biological Psychiatry*. **57** (9), 1052-1060 (2005).
9. Archibald, N.K., Hutton, S.B., Clarke, M.P., Mosimann, U.P., Burn, D.J. Visual exploration in Parkinson's disease and Parkinson's disease dementia. *Brain*. **136** (3), 739-750 (2013).
10. Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Movement Disorders*. **27** (3), 349-356 (2012).
11. Rösler, A. et al. Alterations of visual search strategy in Alzheimer's disease and aging. *Neuropsychology*. **14** (3), 398-408 (2000).
12. Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. *Journal of Neurology Neurosurgery and Psychiatry*. **55** (3), 181-184 (1992).
13. Chiu, H.F.K., Lee, H.C., Chung, W.S., Kwong, P.K. Reliability and Validity of the Cantonese Version of Mini-Mental State Examination-A Preliminary Study. *Hong Kong Journal of*

- 529 *Psychiatry*. **4** (2), 25 (1994).
- 530 14. Wong, A. et al. The validity, reliability and clinical utility of the Hong Kong Montreal  
531 Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease. *Dementia  
532 and Geriatric Cognitive Disorders*. **28** (1), 81–87 (2009).
- 533 15. Fahn, S., Elton, R. Members of the UPDRS Development Committee. Unified Parkinson's  
534 disease rating scale. *Recent Development in Parkinson's Disease*. **2**, 293-304 (1987).
- 535 16. Hoehn, M.M., Yahr, M.D. Parkinsonism: onset, progression, and mortality. *Neurology*  
536 **17**(5), 427-427 (1967).
- 537 17. Wu, P.C., Chang, L. Psychometric properties of the Chinese version of the Beck Depression  
538 Inventory-II using the Rasch model. *Measurement and Evaluation in Counseling and  
539 Development*. **41** (1), 13-31 (2008).
- 540 18. Chiu, H.F. et al. The modified Fuld Verbal Fluency Test: a validation study in Hong Kong.  
541 *The journals of gerontology. Series B, Psychological sciences and social sciences*. **52** (5),  
542 247-250 (1997).
- 543 19. Chan, A.S., Kwok, I. Hong Kong list learning test: manual and preliminary norm. *Hong Kong:  
544 Department of Psychological and Clinical Psychology Center*. (1999).
- 545 20. Robbins, T.W., James, M., Owen, A.M., Sahakian, B.J., McInnes, L., Rabbitt, P. Cambridge  
546 Neuropsychological Test Automated Battery (CANTAB): A Factor Analytic Study of a Large  
547 Sample of Normal Elderly Volunteers. *Dementia and Geriatric Cognitive Disorders*. **5** (5),  
548 266–281 (1994).
- 549 21. Lee, T.M.C., Wang, K. *Neuropsychological Measures: Normative Data for Chinese (revised)*.  
550 (2010).
- 551 22. Birant, D., Kut, A. ST-DBSCAN: An algorithm for clustering spatial-temporal data. *Data and  
552 Knowledge Engineering*. **60** (1), 208-221 (2007).
- 553 23. Wong, O.W. et al. Eye movement parameters and cognitive functions in Parkinson's  
554 disease patients without dementia. *Parkinsonism and Related Disorders*. **52**, 43-48 (2018).
- 555 24. Muslimovic, D., Post, B., Speelman, J.D., Schmand, B. Cognitive profile of patients with  
556 newly diagnosed Parkinson disease. *Neurology*. **65** (8), 1239–1245 (2005).
- 557 25. Winograd-Gurvich, C., Georgiou-Karistianis, N., Fitzgerald, P.B., Millist, L., White, O.B. Self-  
558 paced saccades and saccades to oddball targets in Parkinson's disease. *Brain Research*.  
559 **1106** (1), 134-141 (2006).
- 560 26. Briand, K.A., Strallow, D., Hening, W., Poizner, H., Sereno, A.B. Control of voluntary and  
561 reflexive saccades in Parkinson's disease. *Experimental Brain Research*. **129** (1), 38-48  
562 (1999).
- 563 27. Rivaud-Péchoix, S., Vidailhet, M., Brandel, J.P., Gaymard, B. Mixing pro- and antisaccades  
564 in patients with parkinsonian syndromes. *Brain*. **130** (1), 256-264 (2007).
- 565 28. Pernecky, R., Ghosh, B.C.P., Hughes, L., Carpenter, R.H.S., Barker, R.A., Rowe, J.B. Saccadic  
566 latency in Parkinson's disease correlates with executive function and brain atrophy, but  
567 not motor severity. *Neurobiology of Disease*. **43** (1), 79–85 (2011).
- 568 29. Matsumoto, H. et al. Small saccades restrict visual scanning area in Parkinson's disease.  
569 *Movement Disorders*. **26** (9), 1619-1626 (2011).
- 570 30. MacAskill, M.R., Anderson, T.J., Jones, R.D. Adaptive modification of saccade amplitude in  
571 Parkinson's disease. *Brain*. **125** (7), 1570–1582 (2002).
- 572 31. Salvucci, D.D., Goldberg, J.H. Identifying fixations and saccades in eye-tracking protocols.

573        *Proceedings of the 2000 symposium on Eye tracking research & applications*, 71-78 (2000).  
574    32.    Rana, A.Q., Kabir, A., Dogu, O., Patel, A., Khondker, S. Prevalence of blepharospasm and  
575        apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential  
576        tremor. *European Neurology*. **68** (5), 318-321 (2012).  
577



Figure 1





Figure 2

[Click here to access/download;Figure;Figure 2.tif](#) 




Y F D G T T G T B  
N V G F V F V H V N K G U  
G N F F V J N Q K K B G Z Q  
N F J N G E K F 9  
S K R W N  
E T Y  
M H  
J D R Z H Z E G J C T H X A D S J  
X W E G J C T H X A D S J


Design and Record

Replay


Visualizations




Saccade













Generate



Export Movie

 Recordings

| Name  | ▲ Samples | Participant | ▲ |
|---|-----------|-------------|---|
|  s063 FU   | 88%       | s063 FU     |   |
|  s064     | 99%       | s064        |   |
|  s064 FU | 99%       | s064 FU     |   |
|  s065    | 99%       | s065        |   |
|  s066    | 96%       | s066        |   |
|  s066 FU | 99%       | s066 FU     |   |
|  s067    | 96%       | s067        |   |
|  s067 FU | 95%       | s067 FU     |   |
|  s068    | 94%       | s068        |   |
|  s069    | 85%       | s069        |   |

[Click here to access/download;Figure;Figure 4.tif](#) 




Figure 5

[Click here to access/download;Figure;Figure 5.tif](#)




Figure 6

Design and Record

Replay

Visualizations

Areas of Interest

Statistics

Data Export

Select Data Set

Export Data

Load Settings

Save Settings

Data to export

Participant

Recording

Length

Saccade

i001FU

i001FU

00:04:37.789

Output:

Individual files

Filter:

All Gaze data

File extension:

.atlas

Naming...

Options

Cell format...

Column Order...

☒ GazePointX (ADC5px)

Horizontal coordinate of the averaged left and right eye gaze point on the screen.

Pixels

☒ GazePointY (ADC5px)

Vertical coordinate of the averaged left and right eye gaze point on the screen.

Pixels

Analyzer

Analyzer

Visual Search

Image Set

1

Eye Data

Choose

Action Data

Choose

Algorithm

☒ Tobii (Fill Missing Data Only)

☐ IVDT

Velocity Threshold

200

Dispersion Threshold

45

Window Size

5

☒ ST DBScan

Point Diameter

45

Cluster Size

5

Run

Download

Summary

Summary (Fixation Median as Saccade)

Fixation Data

Saccade Data

Point Data

Visual Data

|  | Control group | Parkinson's group | p-value |
|--|---------------|-------------------|---------|
| <b>Global Cognitive scales</b>   |               |                   |         |
| MMSE   | 28.53 (1.63)  | 28 (1.84)         | 0.09    |
| MoCA   | 27.10 (2.25)  | 26 (2.34)         | 0.009*  |
| <b>Specific Cognitive tests – Frontal executive &amp; Frontal-temporal</b>     |               |                   |         |
| Stocking of Cambridge <sup>a</sup>   | 1.16 (0.14)   | 1.24 (0.19)       | 0.018*  |
| Stroop test <sup>b</sup>   | 1.24 (1.77)   | 1.36 (1.65)       | 0.697   |
| Verbal fluency - animal <sup>b</sup>   | 0.92 (1.47)   | 0.26 (1.31)       | 0.01*   |
| Verbal fluency - fruit <sup>b</sup>  | -0.71 (0.74)  | -1.01 (0.79)      | 0.028*  |
| Verbal fluency - vegetable <sup>b</sup>  | -0.66 (1.04)  | -1.11 (0.90)      | 0.011*  |
| <b>Specific Cognitive tests – Verbal Memory (Hong Kong List Learning Test)</b> |               |                   |         |
| Total learning <sup>b</sup>  | 0.03 (0.90)   | -0.30 (0.87)      | 0.037*  |
| 10 minutes delay free recall <sup>b</sup>                                      | -0.17 (0.90)  | -0.44 (1.10)      | 0.131   |
| 30 minutes delay free recall <sup>b</sup>                                      | -0.19 (0.90)  | -0.39 (1.04)      | 0.206   |
| Recognition score <sup>b</sup>   | 0.10 (1.00)   | 0.15 (0.73)       | 0.722   |
| Discrimination score <sup>b</sup>  | -0.05 (1.02)  | -0.13 (0.97)      | 0.636   |
| <b>Specific Cognitive tests – Visual spatial memory</b>                        |               |                   |         |
| Pattern recognition memory <sup>c</sup>  | 91.33 (9.40)  | 87.77 (10.20)     | 0.045*  |
| <b>Specific Cognitive tests – Attention/Working memory</b>                     |               |                   |         |
| Spatial span <sup>d</sup>  | 6.15 (1.10)   | 5.65 (1.17)       | 0.016*  |



|  | Control group                    | Parkinson's disease group      | p-value |
|--|----------------------------------|--------------------------------|---------|
| Mean fixation duration, in milliseconds (SD) [Range] | 211.59 (24.90) [165.77 - 264.63] | 216.58 (31.64) [145.43-312.68] | 0.331   |
| Mean saccadic amplitude, in degrees (SD) [Range]     | 17.27 (2.49) [13.34 - 22.99]     | 16.36 (2.36) [11.66-23.20]     | 0.037*  |

| Source                 | Dependent Variable         | df | F      | B      |
|------------------------|----------------------------|----|--------|--------|
| Mean fixation duration | Verbal fluency - fruit     | 1  | 5.647  | -0.006 |
|                        | Verbal fluency - vegetable | 1  | 9.744  | -0.009 |
|                        | Recognition score          | 1  | 5.843  | -0.007 |
|                        | Discrimination score       | 1  | 12.771 | -0.011 |
|                        | Pattern recognition memory | 1  | 5.505  | -0.071 |

| Beta   | Std. Error | t      | p-value |
|--------|------------|--------|---------|
| -0.227 | 0.002      | -2.376 | 0.009*  |
| -0.288 | 0.003      | -3.122 | 0.002*  |
| -0.215 | 0.003      | -2.417 | 0.017*  |
| -0.314 | 0.003      | -3.574 | 0.001*  |
| -0.215 | 0.03       | -2.346 | 0.021*  |

| Name of Material/Equipment             | Company   | Catalog Number  |
|--|---|---|
| Computer                               | Intel   |   |
| Computerized cognitive assessment tool | CANTAB  | CANTAB Research Suite   |
| Eye Movement Analyzer                  | Lab Viso Limited  |   |
| Eye tracker                            | Tobii   | Tx300   |
|  | Department of Psychology, The Chinese University of Hong Kong |   |
| Hong Kong List Learning Test           | Laboratory of Neuropsychology, The University of Hong Kong    | The Hong Kong List Learning Test (HKLLT) 2nd Edition                              |
| Stroop test                            | Hong Kong   | Neuropsychological Measures: Normative Data for Chinese, Second Edition (Revised) |
| Tobii Studio                           | Tobii   | Tobii Studio version 3.2.2  |
| Visual Search Task                     | Lab Viso Limited  |   |

## Comments/Description

Contains Pattern Recognition Memory, Spatial Span, and Stockings of Cambridge

<https://github.com/lab-viso-limited/visual-search-analyzer>

23 inch computer screen with resolution of 1920x1080, Sampling rate at 300Hz

Computer programme for running the visual search task

<https://www.labviso.com/#products>



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
[www.jove.com](http://www.jove.com)

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Characterizing the Relationship between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Author(s):

Oscar WH Wong, Sandra Chan

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:

Oscar WH Wong

Department:

Psychiatry


Institution:

Tai Po Hospital

Title:

Dr.

Signature:



Date:

28th March 2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



Vineeta Bajaj, Ph.D.  
Review Editor, Journal of Visualized Experiments  
1 Alewife Center Suite 200 Cambridge MA 02140

11<sup>th</sup> June 2019

Dear Dr. Bajaj,

We would once again like to express our gratitude of the editorial board for the editing work and comments to our manuscript. The changes that we have made are as follows.

1. In line 102 we have removed “Tobii Studio” from the manuscript as suggested.
2. For step 1.4 – 1.7 we have now stated the cutoff score of MMSE/MoCA and the visual acuity. The BDI was just a tool for capturing the depressive symptoms and it was used as a covariate in statistical analysis and there is no cut off/exclusion.
3. Added citation to 1.6, 3.6, 3.9, 3.10. Citation to the Table of Material was added in 3.4 after CANTAB was first mentioned. For the Note after 3.11, the “verbal cognitive task” here is a general term of any cognitive task that involves a strong component of verbal ability. It does not specifically refer to a particular cognitive task and therefore no citation is added here.
4. We have revised the phrasing of point 3.9 – essentially the “problems” are actually scenarios that the subject has to determine the number of moves required to rearrange the balls of the lower display to match that of the upper.
5. All the subjects completing section 3 will proceed to section 4. We have added a point 3.11 to specify that.
6. We have added several figures for better visualisation of the visual search task. First of all the visualisation of the quality of the calibration process is added as Figure 1. There was also an expansion on the description of how to do so on 4.2.3. Secondly, to check for if there are more than 20% missing data, we would use the Samples rate in the Tobii Studio to see how the percentage of the time that the eye position is successfully located by the eye tracker, visualisation of the interface is now shown in Figure 3 and stated in 5.1. Figure 4 and 5 are examples of a typical normal visualised scanpath and a grossly erroneous one respectively and they were mentioned in 5.2. Figure 6 was added to describe the data export process in Tobii Studio with an expansion of the text in 5.4. Lastly, Figure 7 shows the interface of our in-house Visual Search Analyzer.
7. For the programming and coding, we have upload the coding files for the design of the visual search task and how the number and alphabets and number are randomised (Supplementary file 1 & 2 respectively). Alternatively we have also made the programmes (both the task and the Analyzer) available online: <https://www.labviso.com/#products> and would like to seek for the editor’s comment on which way would suit the Journal better. For the Analyser we have also put it on Github (<https://github.com/lab-viso-limited/Eye-Movement-Analyzer>) which shows the coding for the analyzer.

8. We have expanded the section 5 substantially and adding point 4.4.3 to detail the data export and analysis procedure using the Tobii Studio and our own Analyzer.

Once again, thank you for the opportunity to submit our manuscript to JOVE and the effort by the editorial board and reviewers.

Please let us know if there are any issues that require further clarification.

Yours sincerely,

Wong Wing Ho, M.B., Ch.B., FHKCPsych, FHKAM (Psychiatry)  
Assistant Professor,  
Department of Psychiatry,  
The Chinese University of Hong Kong

Tel: +852 61129895

Email: [oscarwhwong@cuhk.edu.hk](mailto:oscarwhwong@cuhk.edu.hk)

# ELSEVIER LICENSE TERMS AND CONDITIONS

May 19, 2019

This Agreement between Dr. Oscar Wong ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

|   |  |
|---|--|
| License Number                                  | 4564160062548  |
| License date                                    | Apr 08, 2019   |
| Licensed Content Publisher                      | Elsevier   |
| Licensed Content Publication                    | Parkinsonism & Related Disorders   |
| Licensed Content Title                          | Eye movement parameters and cognitive functions in Parkinson's disease patients without dementia   |
| Licensed Content Author                         | Oscar WH Wong, Anne YY Chan, Adrian Wong, Claire KY Lau, Jonas HM Yeung, Vincent CT Mok, Linda CW Lam, Sandra Chan                                     |
| Licensed Content Date                           | Jul 1, 2018  |
| Licensed Content Volume                         | 52   |
| Licensed Content Issue                          | n/a  |
| Licensed Content Pages                          | 6  |
| Start Page                                      | 43   |
| End Page  | 48   |
| Type of Use                                     | reuse in a journal/magazine  |
| Requestor type                                  | academic/educational institute   |
| Intended publisher of new work                  | Other  |
| Portion   | figures/tables/illustrations   |
| Number of figures/tables/illustrations          | 3  |
| Format  | electronic   |
| Are you the author of this Elsevier article?    | Yes  |
| Will you be translating?                        | No   |
| Original figure numbers                         | Table 1, Table 2 and Table 3   |
| Title of the article                            | Characterizing the Relationship between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking |
| Publication new article is in                   | Journal of Visualized Experiments  |
| Publisher of the new article                    | MyJove Corp.   |
| Author of new article                           | Oscar Wong   |
| Expected publication date                       | Jul 2019   |
| Estimated size of new article (number of pages) | 5  |

**Requestor Location** Dr. Oscar Wong  
Department office, 1C, Tai Po Hospital  
9 Chuen On Road, Tai Po

Hong Kong, nil nil  
Hong Kong  
Attn: Dr. Oscar Wong

**Publisher Tax ID** GB 494 6272 12

**Total** **0.00 USD**

**Terms and Conditions**

### INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

### GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:  
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [permissions@elsevier.com](mailto:permissions@elsevier.com)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning

this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

### LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

**Posting licensed content on Electronic reserve:** In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. **For journal authors:** the following clauses are applicable in addition to the above:

#### Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

**Accepted Author Manuscripts:** An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
  - via their non-commercial person homepage or blog
  - by updating a preprint in arXiv or RePEc with the accepted manuscript
  - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group
  - directly by providing copies to their students or to research collaborators for their personal use
  - for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
  - via non-commercial hosting platforms such as their institutional repository
  - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI

- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

**Published journal article (JPA):** A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

**Subscription Articles:** If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version.

Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

**Gold Open Access Articles:** May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above: Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

### **Elsevier Open Access Terms and Conditions**

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

#### **Terms & Conditions applicable to all Open Access articles published with Elsevier:**

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

#### **Additional Terms & Conditions applicable to each Creative Commons user license:**

**CC BY:** The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

**CC BY NC SA:** The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

**CC BY NC ND:** The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided

the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

## 20. Other Conditions:

v1.9

Questions? [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.



Click here to access/download  
**Supplemental Coding Files**  
Supplementary File 1.pdf







Click here to access/download  
**Supplemental Coding Files**  
Supplementary File 2.pdf





Click here to access/download  
**Supplemental Coding Files**  
Supplementary File 3.pdf





Click here to access/download  
**Supplemental Coding Files**  
Supplementary File 4.pdf

